Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial

NCT07739147 | Not Yet Recruiting Early Phase 1

• 1 other identifier: PRP-PBM-AGA-RCT-01
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to compare 3 different types of PRP in androgenetic alopecia patients. The main questions it aims to answer: Does Redlight enhanced, Blue light enhanced, or traditional PRP result in higher hair density and health? Does Redlight enhanced, Blue light enhanced, or traditional PRP result in other improved hair metrics. Participants will consent to a PRP treatment but will be blinded to the type. They will then be asked to return for Tricholab analysis at set post-operative timepoints to record changes in hair metrics (Baseline, 1 month, 3 months, 6 months, 9 months, 12 months).

Conditions

Androgenetic Alopecia

Keywords

Androgenetic Alopecia; Hairloss; Trichoscopy; platelet-rich plasma

Outcome Measures

Primary Outcomes (2)

• Hair rate Terminal/Vellus (%)

  Taken from TrichoLab Trichoscopy

  Trichoscopy taken at baseline, 1 month, 2 months, 6 months, 9 months, 12 months

• Hair Density (N/cm^2)

  Taken from TrichoLab Trichoscopy

  Trichoscopy taken at baseline, 1 month, 2 months, 6 months, 9 months, 12 months

Secondary Outcomes (3)

• Hair Density Terminal and Vellus (N/cm^2)

  Trichoscopy taken at baseline, 1 month, 2 months, 6 months, 9 months, 12 months

• Mean Thickness (um)

  Trichoscopy taken at baseline, 1 month, 2 months, 6 months, 9 months, 12 months

• Cumulative Hair Thickness (mm/cm^2)

  Trichoscopy taken at baseline, 1 month, 2 months, 6 months, 9 months, 12 months

Study Arms (3)

Standard PRP

EXPERIMENTAL

Participants assigned to this arm receive autologous PRP injection alone, prepared from their own peripherally drawn injected into the scalp. No adjunctive light therapy or cooling is applied in this arm. (Intervention 1 only)

Drug: Platelet-Rich Plasma (PRP) Injections

Red-Light Enhanced PRP

EXPERIMENTAL

Participants assigned to this arm receive autologous PRP injection, prepared and administered as Arm 1, immediately followed by red-light photobiomodulation therapy delivered via the MetaCell Technologies System, combined with cooling. (Intervention 1 and 2)

Drug: Platelet-Rich Plasma (PRP) Injections; Device: Red-light photobiomodulation with cooling

Blue-Light Enhanced PRP

EXPERIMENTAL

Participants assigned to this arm receive autologous PRP injection, prepared and administered as intervention 1, immediately followed by blue-light photobiomodulation therapy delivered via the MetaCell Technologies System with heating. (Intervention 1 and 3)

Drug: Platelet-Rich Plasma (PRP) Injections; Device: Blue-light photobiomodulation

Interventions

Platelet-Rich Plasma (PRP) Injections DRUG

Autologous platelet-rich plasma prepared from the participant's own peripherally drawn. Blood is processed via centrifugation to concentrate platelets and associated growth factors, then injected into the scalp across the area of hair thinning. Administered at each treatment visit per the study treatment schedule.

Blue-Light Enhanced PRP; Red-Light Enhanced PRP; Standard PRP

Red-light photobiomodulation with cooling DEVICE

Standard Intervention 1 with PRP undergoing additional Stimulus 1: 620 nm, 1 J/cm², 10 minutes; Stimulus 2: 4°C cooling, 15 minutes via MetaCell Technologies System.

Red-Light Enhanced PRP

Blue-light photobiomodulation DEVICE

Standard Intervention 1 with PRP undergoing additional Stimulus 1: 467 nm, 1 J/cm², 10 minutes; Stimulus 2: 37°C, 10 minutes using MetaCell Technologies System.

Blue-Light Enhanced PRP

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18-65
• Diagnosed Androgenetic Alopecia
• Willing to comply with protocol and follow up

You may not qualify if:

• Active scalp infection or disease
• Prior PRP within last 6 months
• Use of hair growth medication topical or oral
• Platelet dysfunction or anticoagulation
• Pregnant or breastfeeding
• history of keloid infection

Sponsors & Collaborators

• Kimberly Meathrel: lead

MeSH Terms

Conditions

Alopecia

Interventions

Injections

Condition Hierarchy (Ancestors)

Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Kimberly Meathrel

  Bespoke Skin MD

  STUDY DIRECTOR

Central Study Contacts

Kimberly E Meathrel, MD, JD, MBA, MSc, FRCSC

CONTACT

16135474182; admin@bespokeskinmd.com

Mya T Clark, BScH

CONTACT

6138752197; admin@bespokeskinmd.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Surgeon and Principal Investigator

Study Record Dates

• First Submitted: July 28, 2026
• First Posted: July 31, 2026
• Study Start (Estimated): December 30, 2026
• Primary Completion (Estimated): December 30, 2027
• Study Completion (Estimated): December 30, 2027
• Last Updated: July 31, 2026

Record last verified: 2026-07